Market Movers: Aligos (ALGS) Gains 7.21% to Close at $1.19 June 21

Equities Staff  |

Aligos Therapeutics Inc (NASDAQ:ALGS) stock was among today's market movers, ending trading up 7.21% to $1.19 on June 21.

236,224 shares traded hands while the 30-day daily average of 255,416 shares.

The company's stock has risen 90.65% so far in 2022.

Aligos shares have moved between $1.03 and $28.39 over the past twelve months.

The company expects its next earnings on 2022-08-04.

For technical charts, analysis, and more on Aligos visit the company profile.

About Aligos Therapeutics Inc

Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the discovery and development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). Aligos’ strategy is to harness the deep expertise and decades of drug development experience its team has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of potentially best-in-class molecules.

To get more information on Aligos Therapeutics Inc and to follow the company's latest updates, you can visit the company's profile page here: Aligos Therapeutics Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

The Best Laid Plans of Mice and Men — Part II
Why I’m Buying the 'New' Value Stocks
Investors Must Understand 5G Wireless Growth Wave: Jeff Kagan
'Goldilocks' Stocks Will Define This Decade



Market Movers

Sponsored Financial Content